Imai T, Katagiri A, Saito K, Tomita Y
Department of Urology, Niigata University School of Medicine, Japan.
Cancer Lett. 1995 Aug 1;94(2):191-7. doi: 10.1016/0304-3835(95)03849-r.
We have shown previously that interferon (IFN)-alpha reduces the sensitivity of renal cell cancer (RCC) cell lines ACHN and KRC/Y to lysis by lymphokine-activated killer (LAK) cells. The close relationship between natural killer (NK) cells and LAK cells prompted us to investigate whether IFN-alpha pretreatment also affects the sensitivity of ACHN cells to lysis by NK cells or IFN-alpha-activated NK cells. A 51Cr-release cytotoxicity assay demonstrated that pretreatment of ACHN with IFN-alpha decreased their susceptibility to NK cells and IFN-alpha-activated NK cells in a dose-dependent manner. Moreover, to investigate the usefulness of 5-fluorouracil (5FU) for combination with IFN-alpha therapy, we examined the effect of preincubation with 5FU on the susceptibility of ACHN. IFN-alpha-induced protection of ACHN from lysis by IFN-alpha-activated NK cells weakened in the presence of 5FU at 0.2 microgram/ml. An adhesion assay showed that preincubation of ACHN with 5FU and IFN-alpha did not alter the adhesion of IFN-alpha-activated NK cells. A cold target competition analysis did not show any difference between untreated and 5FU and/or IFN-alpha-treated competitors. These results suggest that one of the mechanisms of 5FU for combination with IFN-alpha therapy might depend on changes of RCC cells in intrinsic lysability involving a post-binding stage of the lytic cycle to NK cells.
我们之前已经表明,α干扰素(IFN-α)会降低肾细胞癌(RCC)细胞系ACHN和KRC/Y对淋巴因子激活的杀伤细胞(LAK)细胞裂解的敏感性。自然杀伤(NK)细胞与LAK细胞之间的密切关系促使我们研究IFN-α预处理是否也会影响ACHN细胞对NK细胞或IFN-α激活的NK细胞裂解的敏感性。一项51Cr释放细胞毒性试验表明,用IFN-α预处理ACHN细胞会使其对NK细胞和IFN-α激活的NK细胞的敏感性以剂量依赖的方式降低。此外,为了研究5-氟尿嘧啶(5FU)与IFN-α联合治疗的有效性,我们检测了用5FU预孵育对ACHN细胞敏感性的影响。在存在0.2微克/毫升的5FU时,IFN-α诱导的对ACHN细胞免受IFN-α激活的NK细胞裂解的保护作用减弱。一项黏附试验表明,用5FU和IFN-α预孵育ACHN细胞不会改变IFN-α激活的NK细胞的黏附。冷靶竞争分析显示,未处理的竞争者与用5FU和/或IFN-α处理的竞争者之间没有任何差异。这些结果表明,5FU与IFN-α联合治疗的机制之一可能取决于RCC细胞内在可裂解性的变化,这涉及到裂解周期与NK细胞结合后的阶段。